FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Bristol Myers Squibb Manufacturing Abilify Recall

ABILIFY (aripiprazole) Tablets, 30 mg, Rx only, Blister Pack of 100 tablets, Otsuka Ame…

Bristol Myers Squibb Manufacturing Company · Humacao, PR

Risk level
Class II
Reported by FDA
Mar 13, 2013
Recall ID
D-181-2013
Check your lot numberHow we source this data

Summary

Bristol Myers Squibb Manufacturing recalled Abilify starting Nov 2, 2012. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-181-2013 on Mar 13, 2013. Reason: CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed. Status: Terminated.

Why it was recalled

CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.

Product description

ABILIFY (aripiprazole) Tablets, 30 mg, Rx only, Blister Pack of 100 tablets, Otsuka America Pharmaceutical Inc., Bristol-Myers Squibb NDC 59148-011-35

Lot numbers, UPCs & expiration codes

2E69023A, Exp. FEB 28 2015

Where it was sold

LA, TN, CA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-181-2013
Classification
Class II
Status
Terminated
Recall initiated
Nov 2, 2012
FDA report date
Mar 13, 2013
Quantity
21 blister packs
Recall type
Voluntary: Firm initiated
Recalling firm
Bristol Myers Squibb Manufacturing Company

Original FDA data

Every field from FDA enforcement report D-181-2013, exactly as published.

Show all FDA fields
City
Humacao
State
PR
Status
Terminated
Country
United States
Event ID
63706
Address
Rd #3 Km 77.5
Code information
2E69023A, Exp. FEB 28 2015
Postal code
00792
Report date
Mar 13, 2013
Product type
Drugs
Recall number
D-181-2013
Classification
Class II
Recalling firm
Bristol Myers Squibb Manufacturing Company
Product quantity
21 blister packs
Termination date
May 2, 2013
Reason for recall
CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.
Voluntary / mandated
Voluntary: Firm initiated
Product description
ABILIFY (aripiprazole) Tablets, 30 mg, Rx only, Blister Pack of 100 tablets, Otsuka America Pharmaceutical Inc., Bristol-Myers Squibb NDC 59148-011-35
Distribution pattern
LA, TN, CA
Recall initiation date
Nov 2, 2012
Initial firm notification
Telephone
Center classification date
Mar 4, 2013

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-181-2013, published Mar 13, 2013. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls